RNA

Several significant events have impacted Atrium Therapeutics, Inc.'s stock price in the past six months. The company officially launched as a newly independent, publicly traded company on February 27, 2026, following Novartis AG's acquisition of Avidity Biosciences, Inc., leading to a substantial stock price decline. The stock reached its all-time high on March 4, 2026, and a new major risk was identified on March 11, 2026, forecasting a decline in revenue and earnings. The stock reached its all-time low on March 18, 2026. The 50-day moving average moved below the 200-day moving average on March 25, 2026, signaling a potential long-term bearish trend. Atrium Therapeutics announced inducement grants on April 21, 2026, and earned a milestone payment on April 23, 2026. The Momentum Indicator moved below 0 on April 27, 2026, suggesting a potential selling opportunity. The share price declined from May 7, 2025 to May 6, 2026.